WO2007013360A3 - Pancreatic cancer related gene cst6 and gabrp - Google Patents

Pancreatic cancer related gene cst6 and gabrp Download PDF

Info

Publication number
WO2007013360A3
WO2007013360A3 PCT/JP2006/314444 JP2006314444W WO2007013360A3 WO 2007013360 A3 WO2007013360 A3 WO 2007013360A3 JP 2006314444 W JP2006314444 W JP 2006314444W WO 2007013360 A3 WO2007013360 A3 WO 2007013360A3
Authority
WO
WIPO (PCT)
Prior art keywords
pancreatic cancer
cst6
gabrp
related gene
cancer related
Prior art date
Application number
PCT/JP2006/314444
Other languages
French (fr)
Other versions
WO2007013360A2 (en
Inventor
Yusuke Nakamura
Hidewaki Nakagawa
Shuichi Nakatsuru
Original Assignee
Oncotherapy Science Inc
Univ Tokyo
Yusuke Nakamura
Hidewaki Nakagawa
Shuichi Nakatsuru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc, Univ Tokyo, Yusuke Nakamura, Hidewaki Nakagawa, Shuichi Nakatsuru filed Critical Oncotherapy Science Inc
Priority to JP2008503160A priority Critical patent/JP2009505632A/en
Priority to EP06781399A priority patent/EP1907547A2/en
Publication of WO2007013360A2 publication Critical patent/WO2007013360A2/en
Publication of WO2007013360A3 publication Critical patent/WO2007013360A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Plant Pathology (AREA)

Abstract

Objective methods of detecting and diagnosing pancreatic cancer (PDAC) are described herein. In one embodiment, the diagnostic method involves determining the expression level of CST6 or GABRP that discriminates between PDAC cells and normal cells. Finally, the present invention provides methods of screening for therapeutic agents useful in the treatment of pancreatic cancer, methods of treating pancreatic cancer and method of vaccinating a subject against pancreatic cancer.
PCT/JP2006/314444 2005-07-27 2006-07-14 Pancreatic cancer related gene cst6 and gabrp WO2007013360A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2008503160A JP2009505632A (en) 2005-07-27 2006-07-14 Pancreatic cancer-related genes CST6 and GABRP
EP06781399A EP1907547A2 (en) 2005-07-27 2006-07-14 Pancreatic cancer related gene cst6 and gabrp

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70317105P 2005-07-27 2005-07-27
US60/703,171 2005-07-27

Publications (2)

Publication Number Publication Date
WO2007013360A2 WO2007013360A2 (en) 2007-02-01
WO2007013360A3 true WO2007013360A3 (en) 2007-08-30

Family

ID=37075104

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2006/314444 WO2007013360A2 (en) 2005-07-27 2006-07-14 Pancreatic cancer related gene cst6 and gabrp

Country Status (4)

Country Link
EP (1) EP1907547A2 (en)
JP (1) JP2009505632A (en)
CN (1) CN101273131A (en)
WO (1) WO2007013360A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5574258B2 (en) * 2009-10-01 2014-08-20 学校法人東京女子医科大学 Composition for treating pancreatic cancer
CN101985651B (en) * 2010-04-30 2013-09-25 苏州工业园区为真生物医药科技有限公司 New molecular marker for diagnosis and prediction of gastrointestinal tumor
CN103361407A (en) * 2012-04-06 2013-10-23 复旦大学 Application of BRSK2 in preparation of reagents for diagnosing pancreatic cancer
GB201608192D0 (en) * 2016-05-10 2016-06-22 Immunovia Ab Method, array and use thereof
JP2023093779A (en) * 2020-05-21 2023-07-05 国立研究開発法人理化学研究所 Novel anticancer drug
CN115814098A (en) * 2022-12-09 2023-03-21 江南大学 Application of drug resistance related gene GABRP in colorectal cancer drug resistance
CN117305269B (en) * 2023-09-15 2024-04-16 湖北工业大学 Polypeptide based on STYK1 kinase structure and application thereof in preparation of medicines for treating cancers

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6300477B1 (en) * 1995-06-05 2001-10-09 Human Genome Sciences, Inc. Antibodies to human cystatin E
WO2005029082A2 (en) * 2003-09-24 2005-03-31 Progenika Biopharma, S.A. Methods for the in vitro diagnosis and in vitro prognosis of cancer of the pancreas and for the development of drugs against cancer of the pancreas and/or pancreatitis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6300477B1 (en) * 1995-06-05 2001-10-09 Human Genome Sciences, Inc. Antibodies to human cystatin E
US20020052476A1 (en) * 1995-06-05 2002-05-02 Human Genome Sciences, Inc. Human cystatin E
WO2005029082A2 (en) * 2003-09-24 2005-03-31 Progenika Biopharma, S.A. Methods for the in vitro diagnosis and in vitro prognosis of cancer of the pancreas and for the development of drugs against cancer of the pancreas and/or pancreatitis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
IACOBUZIO-DONAHUE CHRISTINE A ET AL: "Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies.", CANCER RESEARCH. 15 DEC 2003, vol. 63, no. 24, 15 December 2003 (2003-12-15), pages 8614 - 8622, XP002403086, ISSN: 0008-5472 *
NAKAMURA TORU ET AL: "Genome-wide cDNA microarray analysis of gene expression profiles in pancreatic cancers using populations of tumor cells and normal ductal epithelial cells selected for purity by laser microdissection", ONCOGENE, BASINGSTOKE, HANTS, GB, vol. 23, no. 13, 25 March 2004 (2004-03-25), pages 2385 - 2400, XP002331614, ISSN: 0950-9232 *

Also Published As

Publication number Publication date
WO2007013360A2 (en) 2007-02-01
EP1907547A2 (en) 2008-04-09
JP2009505632A (en) 2009-02-12
CN101273131A (en) 2008-09-24

Similar Documents

Publication Publication Date Title
WO2004031412A3 (en) Method for diagnosing pancreatic cancer
WO2007013575A3 (en) Method for diagnosing and treating renal cell carcinoma
WO2005028676A3 (en) Method of diagnosing breast cancer
WO2006085684A3 (en) Method of diagnosing bladder cancer
WO2007013360A3 (en) Pancreatic cancer related gene cst6 and gabrp
WO2004031410A3 (en) Method for diagnosing testicular seminomas
WO2004031409A3 (en) Method for diagnosing chronic myeloid leukemia
WO2005028675A3 (en) Methods for detecting, diagnosing and treating hepatocellular carcinomas (hcc)
WO2008067291A3 (en) Method and apparatus for managing glucose control
WO2006042237A3 (en) B7-h1 and methods of diagnosis, prognosis, and treatment of cancer
SG163614A1 (en) Colon cancer related gene tom34
WO2006138219A3 (en) Methods of diagnosis / prognosis of inflammatory conditions
WO2008122670A3 (en) Human diabetes susceptibility tnfrsf10b gene
WO2007032876A3 (en) Biomarkers associated with age-related macular degeneration
WO2007081790A3 (en) Methods for diagnosing and treating prostate cancer
WO2005048818A3 (en) Methods of diagnosing renal disease
WO2010028373A3 (en) Methods for diagnosing cancer and determining the overall survival and disease-free survival of cancer patients
TW200504223A (en) Methods of assessment of drug metabolizing enzymes
WO2004089184A3 (en) NEW USES OF Lp-PLA2 IN COMBINATION TO ASSESS CORONARY RISK
WO2004021010A3 (en) Method of diagnosing colon and gastric cancers
WO2004007770A3 (en) Method for diagnosis of intestinal-type gastric tumors
PT1529116E (en) Method for predicting the responsiveness to treatment with rivastigmine based on the apoe genotyp of dementia patients
EP2738265A3 (en) MHC genes and risk of graft versus host disease
WO2006008124A3 (en) Molecular diagnostic method and treatment in dementia with lewy bodies
WO2009087689A3 (en) Novel primers for identification of astrocytoma, it's grades and glioblastoma prognosis

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680035760.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006781399

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2008503160

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE